Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/15909
Nаziv: | Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice | Аutоri: | Mooranian A. Zamani N. Takechi R. Al-Sallami H. Momir Mikov Svetlana Goločorbin-Kon Božica Kovačević Arfuso F. Al-Salami H. |
Ključnе rеči: | insulin resistance;diabetes;nanoencapsulation;probucol;bile acids | Dаtum izdаvаnjа: | 1-јан-2019 | Čаsоpis: | Therapeutic Delivery | Sažetak: | © 2019 Newlands Press. Aim: Common features in insulin-resistance diabetes include inflammation and liver damage due to bile acid accumulation. Results & methodology: This study aimed to test in vivo pharmacological effects of combining two drugs, ursodeoxycholic acid that has bile acid regulatory effects, and probucol (PB) that has potent anti-oxidative stress effects, using a new poly(meth)acrylate nano-targeting formulation on prediabetic mice. Mice were made diabetic and were fed daily with either PB, nanoencapsulated PB or nanoencapsulated PB-ursodeoxycholic acid before blood, tissues, urine and feces were collected for inflammation and bile acid measurements. The nanoencapsulated PB-ursodeoxycholic acid formulation increased plasma IL-10, and increased the concentration of primary bile acids in the liver and heart. Conclusion: Results suggest potential applications in regulating IL-10 in insulin-resistance prediabetes. | URI: | https://open.uns.ac.rs/handle/123456789/15909 | ISSN: | 20415990 | DOI: | 10.4155/tde-2019-0052 |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
13
prоvеrеnо 10.05.2024.
Prеglеd/i stаnicа
35
Prоtеklа nеdеljа
6
6
Prоtеkli mеsеc
0
0
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.